Monopar Q2 net loss $2.5M, cash $53.3M; ALXN1840 IND transferred, NDA plan for early 2026

Monopar Therapeutics

Net loss $2.5M ($0.35/share) vs $1.7M ($0.49/share) in Q2 2024; R&D up $599k, G&A up $846k.
Cash & equivalents $53.3M; company expects funds to support operations through Dec 2026.
Alexion transferred IND for ALXN1840 (Wilson disease) on June 6, 2025; FDA acknowledged July 29.
Monopar plans to submit NDA for ALXN1840 to FDA in early 2026.
MNPR-101-Zr imaging trial and MNPR-101-Lu therapeutic trial active in Australia; Expanded Access Program enrolling in U.S.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.